Table 2 Outcomes of the meta-analysis
From: Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis
Parameter | Included studies | Sample size | Heterogeneity | OR | 95% CI of overall effect | P value | |
|---|---|---|---|---|---|---|---|
KIT mutation-positive | KIT mutation-negative | ||||||
Age (≥40 years) | 7 | 308 | 179 | P = 0.26, I2 = 22.4% | 1.08 | 0.72 to 1.61 | P = 0.72 |
Gender (male) | 12 | 517 | 348 | P = 0.35, I2 = 9.7% | 1.02 | 0.77 to 1.35 | P = 0.90 |
KIT expression | 5 | 224 | 200 | P = 0.29, I2 = 20.2% | 2.79 | 1.49 to 5.21 | P = 0.001 |
Cell type (spindle cell) | 9 | 450 | 278 | P = 0.007, I2 = 61.7% | 3.19 | 1.71 to 5.93 | P = 0.0003 |
Primary tumor site (stomach) | 11 | 629 | 356 | P = 0.41, I2 = 3.2% | 0.56 | 0.43 to 0.74 | P <0.0001 |
Tumor size (>5 cm) | 8 | 319 | 218 | P = 0.05, I2 = 50.8% | 1.74 | 1.20 to 2.53 | P = 0.003 |
Mitotic count (>5) | 8 | 382 | 263 | P = 0.02, I2 = 57.8% | 2.00 | 1.08 to 3.68 | P = 0.03 |
Recurrence | 8 | 424 | 268 | P = 0.10, I2 = 42.1% | 2.06 | 1.37 to 3.11 | P = 0.0005 |
Metastasis | 6 | 239 | 153 | P = 0.31, I2 = 16.5% | 2.77 | 1.64 to 4.67 | P = 0.0001 |
3-year overall survival | 6 | 95 | 106 | P = 0.24, I2 = 25.8% | 0.47 | 0.25 to 0.90 | P = 0.02 |